MissionIR Articles
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Aims to Deliver Safer Alternative for Nicotine Experience
Lexaria Bioscience Corp. (NASDAQ: LEXX) will soon begin a human clinical study, NIC-H22-1, to compare its DehydraTECH-nicotine pouch performance with that of existing brands such as ON! and Zyn, currently available in the U.S. “Animal…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Devoting Research, Product Development to Make Drug Substances More Effective
Lexaria Bioscience Corp. (NASDAQ: LEXX) is devoting its research and product development to making drug substances more effective in the approach to treating medical conditions such as high blood pressure and, in the process, to…
-
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Technology Influencing the Pharmaceutical Industry
Lexaria began its human clinical study on oral nicotine alternatives, evaluating the effectiveness of its DehydraTECH-nicotine pouch performance Earlier in the year, the company also announced the commencement of its HYPER-H21-4 human clinical study on…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-Nicotine Pouch Performance to Be Compared to That of Leading Brands
Lexaria Bioscience Corp. (NASDAQ: LEXX) is expected to begin dosing for the NIC-H22-1 human study this summer. “NIC-H22-1, a pharmacokinetic randomized, double-blinded, cross-over study involving 36 human participants, will compare Lexaria’s DehydraTECH-nicotine pouch performance to…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Readying Human Study to Compare Lexaria’s DehydraTECH-Nicotine Pouch Performance to that of Existing Leading Brands
In its most recent oral nicotine study, Lexaria established that DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls and peak levels achieved were up to 10x higher than controls Lexaria hopes…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Update on its Patented DehydraTECH(TM) Technology, Including the Approval of New Patent
Lexaria received its 25th patent – and the first patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs The company is seeking IND approval from the FDA and has commenced…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands its Patent Portfolio With New Patent for Antiviral Drug Delivery with DehydraTECH
Lexaria just received another patent for DehydraTECH(TM): this time for the enhanced delivery of antiviral drugs This becomes the company’s 25th patent granted worldwide and the 10th granted in the U.S. It adds to the…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Unlock Capabilities of Revolutionary DehydraTECH(TM) Platform
Lexaria Bioscience Corp. (NASDAQ: LEXX) is aware of the need to continuously improve its understanding of the capabilities and potential applications of its patented DehydraTECH(TM) drug delivery technology. This informs its long-held commitment to its…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Advancing DehydraTECH-Nicotine Research to Support Safer, More Effective Oral Alternative to Harmful Pulmonary Administration Practices
Lexaria expects to begin dosing this summer as part of a human nicotine study, NIC-H22-1, to compare DehydraTECH-nicotine pouch performance to that of existing leading brands such as ON! and Zyn So far, the company’s…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures First-Ever Patent for DehydraTECH to Deliver Antiviral Drugs
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of its first-ever patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs. According to…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences Its Most Comprehensive Study to Date
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has begun its multi-week human clinical hypertension study. The randomized, double blinded, placebo-controlled, cross-over study in 60 people, HYPER-H21-4,…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Advances its Human Nicotine Study and Announces New Nicotine Formulation Creation and Evaluation Program with Altria
Lexaria’s patented DehydraTECH(TM) technology has proven, in the NIC-A21-1 animal study, to be 10-20 times faster in reaching peak delivery of nicotine to the bloodstream than controls The company hopes to affirm this in the…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Results from Pulmonary Hypertension Clinical Study
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has released data from its HYPER-H21-3 human study. The company noted that data from its simulated pulmonary hypertension clinical study indicate positive safety and efficacy…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Update on Human Nicotine Study NIC-H22-1
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced details of human nicotine study NIC-H22-1, which is expected to begin dosing this summer. According to the announcement, NIC-H22-1 is a…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX): A Review of Its Research Developments
Lexaria Bioscience, the global innovator behind DehydraTECH drug delivery technology, has continuously focused on research into its patented technology The company has conducted both in vitro testing and in vivo animal and human testing to…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Beginning of New Nicotine Formulation Creation, Evaluation Program
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has entered agreements with Altria Client Services LLC. According to the announcement, the agreements call for Lexaria to provide specific DehydraTECH(TM) powder-based nicotine formulations for…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Hopes to Demonstrate DehydraTECH’s Superior Performance in Ongoing Epilepsy Research Program
Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced the beginning of the first phase of its epilepsy research program, EPIL-A21-1. “The research program will assess the seizure-inhibiting activity of cannabidiol (‘CBD’) administered via the company’s proprietary…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Exploring Multiple Strong Market Paths
Lexaria is a global innovator that has developed the patented DehydraTECH(TM) technology that improves bioavailability, speed of onset, and brain absorption of active pharmaceutical ingredients (“APIs”) The company strategically partners with third-party organizations seeking to…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Technology Continues to Showcase Ability to Improve Effectiveness of Existing Drug Brands
Health and wellness drug product innovator Lexaria Bioscience has developed a patented technology — DehydraTECH (TM) — which enhances the bioavailability of fat-soluble drugs and molecules Lexaria continues to research DehydraTECH’s ability to improve the…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) 24th Patent Sets the Stage for New Market Opportunities in Australia
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, celebrated the receipt of its 24th granted patent entitled “Compositions Infused with Nicotine Compounds and Methods of Use Thereof.” Granted in Australia, this…
Search Articles
Latest Articles
- Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ): Advancing a Premier North American Copper District
- MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at Emerging Growth Conference on August 20
- Safe Pro Group Inc. (NASDAQ: SPAI) Advanced AI Patent Protections with Notification Publications in Australia, Israel, and the European Region
- MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q2 2025 Results, Highlights Progress Across Lead Programs and Strategic Investment
- MissionIRNewsBreaks – Vision Marine Technologies Inc. (NASDAQ: VMAR) Prices $7 Million Public Offering of Common Stock and Pre-Funded Warrants